Jorge Cortes, MD - Third-Line Therapies in Chronic Myeloid Leukemia: Evolving to Overcome the Limitations of Early-Generation Tyrosine Kinase Inhibitors

Please visit answersincme.com/RPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses available third-line therapies for patients with chronic myeloid leukemia. Upon completion of this activity, participants should be better able to: Describe treatment challenges with available therapeutic options as chronic myeloid leukemia (CML) progresses; Review the available clinical data for third-line agents in CML; and Differentiate between third-line CML treatments based on patient, drug, and disease factors.

There are no comments yet.

Please log in to write the first comment.